Sepsis and COVID-19 are major burden for populations worldwide. In sepsis/COVID-19, a dysregulated host response to infection is the hallmark supporting the routine use of corticosteroids (CS), a low-cost and highly efficient class of immunomodulators. Stratifying patients based on individual immune response may improve the balance of benefit-to-risk of CS treatment.

iRECORDS will generate signatures of CS sensitivity/resistance of individual septic/COVID-19 patients. These signatures will be based on characterisations of biological systems by using targeted approaches at levels of DNA, RNA, proteins (i.e. cytokines), hormones, and metabolites. We will use Artificial Intelligence methods to develop efficient signatures by integrating the high dimensional multi-level data from previous studies and newly generated data. The resulting signatures will define personalised treatment rules for patients, and thereby improve their chance to survive.